Search for a command to run...
<italic>In vitro</italic> mode of action of ivy leaf dry extract EA575 is well documented, but so far <italic>in vivo</italic> data to extrapolate cellular mechanisms into a physiological context is scarce. This study evaluated anti-inflammatory effects of EA575 in a mouse model of bleomycin-induced acute lung inflammation. EA575 was administered twice daily by oral gavage for 3 or 7 days (d) with 21.5, 107.6, and 215.25 mg/kg bw/d following bleomycin challenge. Upon study termination, cytology and cytokine levels were analyzed in bronchoalveolar lavage fluid (BALF) and histopathology incl. goblet cell metaplasia assessment was carried out. EA575 treatment reduced inflammatory cell influx, namely neutrophils, lymphocytes, and macrophages, in both BALF and lung tissue after 3 & 7 d. Cytokine levels (e.g., IL-6, TNF-α) in BALF were dose-dependently reduced at day 3 & 7. Goblet cell metaplasia pathology score was decreased dose-dependently after 3 & 7 d, suggesting reduced mucus production. The results highlight the benefits of EA575 in treating acute inflammation-related respiratory diseases by reducing inflammation and excessive mucus production by goblet cells. <fig><object-id>erj;66/suppl_69/PA3599/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> Figure 1: EA575 reduces goblet cell metaplasia in lungs of bleomycin (BLM)-challenged mice. Pathology score: 0 – absent, 1 – minimal, 2 – mild, 3 – moderate, 4 – severe. Data is shown as mean ± SD (n=5-8), for statistics ANOVA followed by Dunnett’s test was applied (* p≤0.05, ** p≤0.01, *** p ≤0.001).